Jinal L. Chaudhary, Sanjesh G Rathi, Sanket Shah, Jigna T Patel, Sohansinh Vaghela
Jinal L. Chaudhary*, Sanjesh G Rathi, Sanket Shah, Jigna T Patel, Sohansinh Vaghela
Department of Pharmacy Practice Saraswati Institute of Pharmaceutical Sciences, Dhanap, Ghandhinagar.
Volume - 14,
Issue - 2,
Year - 2021
The present study was on Deferiprone is the first line therapy in treatment of thalassemia patients either alone or in combination with other available chelating agents. Advantage over other iron chelators is, oral mode of administration, better compliance, being more affordable, similar efficacy in reducing iron burden in patients with severe haemosiderosis. Long-term Deferiprone therapy is generally well tolerated, and a longer duration of therapy is warranted in patients with severe iron overload. Deferiprone offers an acceptable second line alternative. Patients with thalassemia major for whom deferoxamine therapy is contra-indicated or who present serious toxicity with deferoxamine therapy. A comparison between the pre-clinical data and the safety data is very difficult in this case. The most important adverse reactions are agranulocytosis and neutropenia whose incidence is 1.2% and 6% respectively. The amount of long-term data is limited, but in view of the indication this was accepted. As a weekly monitoring of blood counts is accepted for the safety of the product.
Cite this article:
Jinal L. Chaudhary, Sanjesh G Rathi, Sanket Shah, Jigna T Patel, Sohansinh Vaghela. Deferiprone (Ferriprox) as newer iron Chelator in Thalassaemia major patients. Research J. Pharm. and Tech. 2021; 14(2):1041-1044. doi: 10.5958/0974-360X.2021.00186.4
Jinal L. Chaudhary, Sanjesh G Rathi, Sanket Shah, Jigna T Patel, Sohansinh Vaghela. Deferiprone (Ferriprox) as newer iron Chelator in Thalassaemia major patients. Research J. Pharm. and Tech. 2021; 14(2):1041-1044. doi: 10.5958/0974-360X.2021.00186.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-2-82
1. Singer T, MD, Hematologist, Children’s Hospital & Research Center Oakland Perspectives, Newsletter of the Northern California Thalassemia Center - fall 2005 p-4
2. Suh KR, MD, PhD, “Ferriprox (Deferiprone) NDA 21-825 FDA Presentation to Oncologic Drugs Advisory Committee. 2011; 1-37.
3. Ferriprox, “The Initial Scientific Discussion and Scientific Discussion on Procedures, which have been Finalized Before 1 June 2004” @ EMEA 2005, 1.
4. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J, 2001; 22: 2171–79.
5. Westwood M, Anderson L, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging, 2003; 18:33–39.
6. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, and Hilgartner MW Prolonged survival in patients with beta-thalassemia major treated with deferioxamine. J Pediatr ,1991;540–545
7. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Kousa S. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassemia patients. Br J Hematol, 2003; 121:187–189.